ArticleBlood2024

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

Sattva S Neelapu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.